Revelation Biosciences (REVB) Competitors $2.62 +0.05 (+1.75%) As of 01:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock REVB vs. NERV, BCTX, BGXX, CLRB, AFMD, ABP, LSB, TLPH, PHXM, and ATHAShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Minerva Neurosciences (NERV), BriaCell Therapeutics (BCTX), Bright Green (BGXX), Cellectar Biosciences (CLRB), Affimed (AFMD), Abpro (ABP), Lakeshore Biopharma (LSB), Talphera (TLPH), PHAXIAM Therapeutics (PHXM), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Minerva Neurosciences BriaCell Therapeutics Bright Green Cellectar Biosciences Affimed Abpro Lakeshore Biopharma Talphera PHAXIAM Therapeutics Athira Pharma Minerva Neurosciences (NASDAQ:NERV) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings. Does the MarketBeat Community believe in NERV or REVB? Minerva Neurosciences received 317 more outperform votes than Revelation Biosciences when rated by MarketBeat users. However, 63.83% of users gave Revelation Biosciences an outperform vote while only 55.52% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34755.52% Underperform Votes27844.48% Revelation BiosciencesOutperform Votes3063.83% Underperform Votes1736.17% Does the media refer more to NERV or REVB? In the previous week, Minerva Neurosciences had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for Revelation Biosciences. Minerva Neurosciences' average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score. Company Overall Sentiment Minerva Neurosciences Neutral Revelation Biosciences Neutral Do insiders & institutionals have more ownership in NERV or REVB? 34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 0.1% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, NERV or REVB? Revelation Biosciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M$0.821.77Revelation BiosciencesN/AN/A-$120K-$102.61-0.03 Do analysts rate NERV or REVB? Minerva Neurosciences currently has a consensus price target of $5.00, suggesting a potential upside of 244.83%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Minerva Neurosciences is more favorable than Revelation Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is NERV or REVB more profitable? Minerva Neurosciences' return on equity of 0.00% beat Revelation Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% Revelation Biosciences N/A -193.51%-84.00% Which has more risk and volatility, NERV or REVB? Minerva Neurosciences has a beta of -0.5, meaning that its stock price is 150% less volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. SummaryMinerva Neurosciences beats Revelation Biosciences on 9 of the 13 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.33M$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E Ratio-0.018.9226.8019.71Price / SalesN/A252.24389.55117.28Price / CashN/A65.8538.2534.62Price / Book0.016.466.804.50Net Income-$120,000.00$143.98M$3.23B$248.18M7 Day Performance-15.18%2.03%1.53%0.23%1 Month Performance-19.69%4.11%10.05%12.39%1 Year Performance-92.09%-2.87%16.75%7.07% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences0.5645 of 5 stars$2.62+1.8%N/A-91.8%$2.37MN/A-0.0110Analyst DowngradeNERVMinerva Neurosciences2.9324 of 5 stars$1.66+2.9%$5.00+201.9%-41.1%$11.58MN/A-3.769News CoverageAnalyst ForecastGap UpBCTXBriaCell Therapeutics1.3105 of 5 stars$3.12+0.3%$32.00+925.6%-84.5%$11.57MN/A-0.238BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002News CoverageGap DownCLRBCellectar Biosciences2.3061 of 5 stars$0.26+6.8%$12.50+4,633.1%-92.3%$11.40MN/A-0.1510Analyst ForecastAFMDAffimed4.3862 of 5 stars$0.69+1.2%$13.50+1,848.1%-96.5%$11.03M$877,000.000.00200Analyst ForecastAnalyst RevisionABPAbproN/A$0.21+4.9%$4.00+1,806.6%N/A$10.96M$183,000.000.0015Earnings ReportGap DownHigh Trading VolumeLSBLakeshore Biopharma0.7068 of 5 stars$1.16+1.8%N/AN/A$10.80M$672.27M0.00773Positive NewsGap UpHigh Trading VolumeTLPHTalphera2.8182 of 5 stars$0.52-3.4%$5.00+858.8%-51.8%$10.69M$281,000.00-0.7619Gap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049ATHAAthira Pharma1.7032 of 5 stars$0.27+6.2%$13.83+5,023.5%-89.4%$10.54MN/A-0.0940Gap Down Related Companies and Tools Related Companies Minerva Neurosciences Competitors BriaCell Therapeutics Competitors Bright Green Competitors Cellectar Biosciences Competitors Affimed Competitors Abpro Competitors Lakeshore Biopharma Competitors Talphera Competitors PHAXIAM Therapeutics Competitors Athira Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REVB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Bloodbath Coming on June 1st?If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy REVB Stock Free REVB Stock Alerts